



LKT Laboratories, Inc.

PAC-1

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID P004080

CAS No. 315183-21-2

Chemical Name N'-[(6-oxo-5-prop-2-enyl-1-cyclohexa-2,4-dienylidene)methyl]-2-[4-(phenylmethyl)-1-piperazinyl]acetohydrazide

Synonym (4-Benzylpiperazino)acetic acid (3-allyl-2-hydroxybenzylidene)hydrazide, 1-Piperazineacetic acid, 2-(phenylmethyl)-, [[2-hydroxy-3-(2-propenyl)phenyl]methylene]hyrrazide


Formula C₂₃H₂₈N₄O₂

Formula Wt. 392.50

Melting Point

Purity ≥98%

Solubility 100mM in DMSO



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
P004080	5 mg	\$67.80
P004080	25 mg	\$180.30
P004080	100 mg	\$525.90

Store Temp 4° C

Ship Temp Ambient

Description PAC-1 (Procaspase Activating Compound 1) has been identified through high-throughput screening as a compound that may enhance the enzymatic activity of procaspase-3 in vitro. Procaspase-3 may be useful as an anticancer strategy due to its low frequency of mutations in cancer and expression of its enzyme in several types of cancers. PAC-1 converts procaspase-3 to active caspase-3 in vitro by chelating zinc ions and thereby inducing cell death in the tumor cells. In multiple cancer cell lines, PAC-1 was shown to trigger endoplasmic reticulum stress signaling and induce autophagy and mitochondria-mediated apoptosis.

References Sarkar A, Balakrishnan K, Chen J, et al. Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. *Oncotarget*. 2016 Jan 19;7(3):3461-3476. PMID: 26658105.

Roth HS, Hergenrother PJ. Derivatives of procaspase-activating compound 1 (PAC-1) and their anticancer activities. *Curr Med Chem*. 2016;23(3):201-241. PMID: 26630918.

Seervi M, Sobhan PK, Joseph J, et al. ERO1alpha-dependent endoplasmic reticulum-mitochondrial calcium flux contributes to ER stress and mitochondrial permeabilization by procaspase-activating compound-1 (PAC-1). *Cell Death Dis*. 2013 Dec 19;4:e968. PMID: 24357799.

Lucas PW, Schmit JM, Peterson QP, et al. Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs. *Invest New Drugs*. 2011 Oct;29(5):901-911. PMID: 20499133.

Peterson QP, Goode DR, West DC, et al. PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. *J Mol Biol*. 2009 Apr 24;388(1):144-158. PMID: 19281821.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.